Design, synthesis and evaluation of novel hybrids between 4-anilinoquinazolines and substituted triazoles as potent cytotoxic agents. 2018

Giang Le-Nhat-Thuy, and Thuy Van Dinh, and Hai Pham-The, and Hung Nguyen Quang, and Nga Nguyen Thi, and Tuyet Anh Dang Thi, and Phuong Hoang Thi, and Tu Anh Le Thi, and Ha Thanh Nguyen, and Phuong Nguyen Thanh, and Trung Le Duc, and Tuyen Van Nguyen
Institute of Chemistry, Vietnam Academy of Science and Technology, 18-Hoang Quoc Viet, Cau Giay, Hanoi, Viet Nam; Graduate University of Science and Technology, Vietnam Academy of Science and Technology, 18 Hoang Quoc Viet, Cau Giay, Hanoi, Viet Nam.

In this research several series of novel dioxygenated ring fused 4-anilinoquinazolines (10a-d) and 4-anilinoquinazoline-substituted triazole hybrid compounds (11-14) have been designed and synthesized. Their biological significance was highlighted by evaluating in vitro for anticancer activities, wherein several compounds displayed excellent activity specifically against three human cancer cell lines (KB, epidermoid carcinoma; HepG2, hepatoma carcinoma; SK-Lu-1, non-small lung cancer). Especially, compound 13a exhibited up to 100-fold higher cytotoxicity in comparison with erlotinib. Docking the most cytotoxic compounds (11d, 13a, 13b, and 14c) into the ATP binding site of different EGFR tyrosine kinase domains was perfomed to predict the analogous binding mode of these compounds to the EGFR targets.

UI MeSH Term Description Entries
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D011799 Quinazolines A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring. Quinazoline
D004354 Drug Screening Assays, Antitumor Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals. Anticancer Drug Sensitivity Tests,Antitumor Drug Screens,Cancer Drug Tests,Drug Screening Tests, Tumor-Specific,Dye Exclusion Assays, Antitumor,Anti-Cancer Drug Screens,Antitumor Drug Screening Assays,Tumor-Specific Drug Screening Tests,Anti Cancer Drug Screens,Anti-Cancer Drug Screen,Antitumor Drug Screen,Cancer Drug Test,Drug Screen, Anti-Cancer,Drug Screen, Antitumor,Drug Screening Tests, Tumor Specific,Drug Screens, Anti-Cancer,Drug Screens, Antitumor,Drug Test, Cancer,Drug Tests, Cancer,Screen, Anti-Cancer Drug,Screen, Antitumor Drug,Screens, Anti-Cancer Drug,Screens, Antitumor Drug,Test, Cancer Drug,Tests, Cancer Drug,Tumor Specific Drug Screening Tests
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein
D000814 Aniline Compounds Compounds that include the aminobenzene structure. Phenylamine,Phenylamines,Anilines,Compounds, Aniline
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D014230 Triazoles Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3. Triazole
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs

Related Publications

Giang Le-Nhat-Thuy, and Thuy Van Dinh, and Hai Pham-The, and Hung Nguyen Quang, and Nga Nguyen Thi, and Tuyet Anh Dang Thi, and Phuong Hoang Thi, and Tu Anh Le Thi, and Ha Thanh Nguyen, and Phuong Nguyen Thanh, and Trung Le Duc, and Tuyen Van Nguyen
October 2020, Chemical biology & drug design,
Giang Le-Nhat-Thuy, and Thuy Van Dinh, and Hai Pham-The, and Hung Nguyen Quang, and Nga Nguyen Thi, and Tuyet Anh Dang Thi, and Phuong Hoang Thi, and Tu Anh Le Thi, and Ha Thanh Nguyen, and Phuong Nguyen Thanh, and Trung Le Duc, and Tuyen Van Nguyen
January 2018, Anti-cancer agents in medicinal chemistry,
Giang Le-Nhat-Thuy, and Thuy Van Dinh, and Hai Pham-The, and Hung Nguyen Quang, and Nga Nguyen Thi, and Tuyet Anh Dang Thi, and Phuong Hoang Thi, and Tu Anh Le Thi, and Ha Thanh Nguyen, and Phuong Nguyen Thanh, and Trung Le Duc, and Tuyen Van Nguyen
December 2019, Bioorganic & medicinal chemistry letters,
Giang Le-Nhat-Thuy, and Thuy Van Dinh, and Hai Pham-The, and Hung Nguyen Quang, and Nga Nguyen Thi, and Tuyet Anh Dang Thi, and Phuong Hoang Thi, and Tu Anh Le Thi, and Ha Thanh Nguyen, and Phuong Nguyen Thanh, and Trung Le Duc, and Tuyen Van Nguyen
September 2014, Bioorganic & medicinal chemistry letters,
Giang Le-Nhat-Thuy, and Thuy Van Dinh, and Hai Pham-The, and Hung Nguyen Quang, and Nga Nguyen Thi, and Tuyet Anh Dang Thi, and Phuong Hoang Thi, and Tu Anh Le Thi, and Ha Thanh Nguyen, and Phuong Nguyen Thanh, and Trung Le Duc, and Tuyen Van Nguyen
August 2022, European journal of medicinal chemistry,
Giang Le-Nhat-Thuy, and Thuy Van Dinh, and Hai Pham-The, and Hung Nguyen Quang, and Nga Nguyen Thi, and Tuyet Anh Dang Thi, and Phuong Hoang Thi, and Tu Anh Le Thi, and Ha Thanh Nguyen, and Phuong Nguyen Thanh, and Trung Le Duc, and Tuyen Van Nguyen
August 2016, Bioorganic & medicinal chemistry letters,
Giang Le-Nhat-Thuy, and Thuy Van Dinh, and Hai Pham-The, and Hung Nguyen Quang, and Nga Nguyen Thi, and Tuyet Anh Dang Thi, and Phuong Hoang Thi, and Tu Anh Le Thi, and Ha Thanh Nguyen, and Phuong Nguyen Thanh, and Trung Le Duc, and Tuyen Van Nguyen
September 2018, Molecules (Basel, Switzerland),
Giang Le-Nhat-Thuy, and Thuy Van Dinh, and Hai Pham-The, and Hung Nguyen Quang, and Nga Nguyen Thi, and Tuyet Anh Dang Thi, and Phuong Hoang Thi, and Tu Anh Le Thi, and Ha Thanh Nguyen, and Phuong Nguyen Thanh, and Trung Le Duc, and Tuyen Van Nguyen
November 2014, Molecules (Basel, Switzerland),
Giang Le-Nhat-Thuy, and Thuy Van Dinh, and Hai Pham-The, and Hung Nguyen Quang, and Nga Nguyen Thi, and Tuyet Anh Dang Thi, and Phuong Hoang Thi, and Tu Anh Le Thi, and Ha Thanh Nguyen, and Phuong Nguyen Thanh, and Trung Le Duc, and Tuyen Van Nguyen
February 2022, Archiv der Pharmazie,
Giang Le-Nhat-Thuy, and Thuy Van Dinh, and Hai Pham-The, and Hung Nguyen Quang, and Nga Nguyen Thi, and Tuyet Anh Dang Thi, and Phuong Hoang Thi, and Tu Anh Le Thi, and Ha Thanh Nguyen, and Phuong Nguyen Thanh, and Trung Le Duc, and Tuyen Van Nguyen
August 2014, Bioorganic & medicinal chemistry letters,
Copied contents to your clipboard!